|
Found 48 result(s) FROM 1963 pages containing the term 'alendronate'.
Wednesday Jan 07, 2009
Study Links Osteoporosis Drugs to Jaw Trouble
People taking oral osteoporosis drugs may have a higher risk of developing jaw trouble than previously thought...
Thursday Nov 20, 2008
FDA Says Bisphosphonates Do Not Cause Atrial Fibrillation
The FDA has concluded that there is no causal link between the use of bisphosphonates and atrial fibrillation...
Wednesday Oct 29, 2008
Denosumab Bests Alendronate for Increasing Bone Mass
One year of denosumab was more likely to produce a 3% gain in hip or spine bone mass than one year of alendronate...
Thursday Oct 16, 2008
Novartis Reports Once-Yearly Aclasta® Approved in EU to Treat Osteoporosis in Men; Label to Include Reduction of New Fractures Following Hip Fracture in Men and Postmenopausal Women
The European Commission followed the US FDA in approving once-yearly Aclasta for the treatment of osteoporosis in men who are at increased risk of fractures, and has broadened the drug’s label to include reduction of new fractures in men and postmenopausal women with osteoporosis who have recently suffered a hip fracture...
Friday Sep 26, 2008
ASBMR Reports Show 68% Drop in Spinal Fractures With Denosumab, Stronger Effect on Bone Turnover Than With Alendronate, High Patient Preference
Studies reported at the 2008 ASBMR meeting showed that denosumab, which is given twice yearly, was as effective as the best competing agents at preventing osteoporotic fractures. Denosumab produced greater gains in BMD than alendronate and was preferred to once-weekly oral alendronate...
Wednesday Aug 20, 2008
Zoledronic Acid Prevents Chemo-Induced Bone Loss in Premenopausal Women With Breast Cancer
As the population of breast cancer survivors grows, the risks of life after cancer treatment are becoming a major concern. One risk is bone loss caused by chemotherapy, and phase III data show that a dose of zoledronic acid every 3 months during chemotherapy can prevent this problem in premenopausal women with breast cancer...
Wednesday Jun 25, 2008
Endocrinologists Wrestle With Question of How Long to Continue Bisphosphonate Therapy for Osteoporosis
The jury is still out when it comes to how long bisphosphonate therapy should be continued…
Wednesday May 21, 2008
Amgen’s 2nd Phase III Denosumab Osteoporosis Study Meets Primary, Secondary BMD Endpoints in Alendronate Transition Study; Transition Patients Achieved Superior Gains in BMD
Amgen's trial comparing the effects of denosumab vs continued alendronate therapy on bone mineral density demonstrated superior results for primary and all secondary endpoints...
Tuesday Apr 29, 2008
Alendronate Linked to Atrial Fibrillation
A case-control study reports that women who have used alendronate are nearly twice as likely to develop atrial fibrillation as those who have never used bisphosphonates...
Wednesday Apr 16, 2008
Lilly’s Forsteo® Receives Approval From European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis
Eli Lilly and Co announced that the European Commission has approved a new indication for Forsteo® (teriparatide [rDNA origin] injection) for the treatment of sustained, systemic glucocorticoid-induced osteoporosis (GIOP) in adults at increased risk for fracture...
Tuesday Mar 11, 2008
Lilly’s Forsteo® Receives Positive Opinion From European Committee for Medicinal Products for Human Use to Treat Glucocorticoid-Induced Osteoporosis
Eli Lilly and Co announced that they have received a positive opinion recommending approval of Forsteo® (teriparatide [rDNA origin] injection) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in adults at increased risk for fracture...
Tuesday Mar 11, 2008
AAOS Researchers Warn of Alendronate Fracture Risk
Two studies reported at the AAOS meeting warned of a possible increase in risk of low-energy or stress fractures associated with long-term use of alendronate...
Thursday Feb 07, 2008
Watson, Barr, Teva Launch Generic Fosamax® (Alendronate Sodium) Tablets
Watson Pharmaceuticals, Inc; Barr Pharmaceuticals, Inc; and Teva Pharmaceutical Industries Ltd; have announced launches of the generic version of Merck & Co, Inc's Fosamax® tablets...
Monday Feb 04, 2008
Cochrane Review: Alendronate Safe, Effective for Secondary Fracture Prevention
Alendronate can stave off vertebral, nonvertebral, hip, and wrist fractures among postmenopausal women with low bone density and/or those with previous fractures...
Thursday Jan 31, 2008
Alendronate Decreases TRACP 5b Activity in Osteoarthritic Bone
Bisphosphonates may reduce TRACP 5b activity in the intertrochanteric area of the femoral head, suggesting that they are most effective in areas of well-supplied bone...
Monday Jan 28, 2008
Amgen Reports Denosumab Osteoporosis Study Met Primary and All Secondary BMD Endpoints in a Direct Comparison With Weekly Alendronate (Fosamax®)
Amgen Inc announced findings from a head-to-head, double-blind study comparing the effects of twice-yearly subcutaneous injections of denosumab versus weekly oral doses of alendronate in postmenopausal women with low bone mineral density...
Friday Jan 18, 2008
Bone Experts Slam New UK Limits on Osteoporosis Drugs
Some of the biggest names in osteoporosis have signed on to two papers in Bone that criticize the latest UK National Institute for Health and Clinical Excellence (NICE) recommendations on drugs for prevention of osteoporotic fractures, in essence charging that the agency gamed its analysis to cut costs for the National Health Service...
Monday Nov 26, 2007
Teriparatide Builds More Bone Than Alendronate in Steroid-Caused Osteoporosis
Teriparatide built more bone mass and prevented more vertebral fractures than alendronate in the first head-to-head study of the two drugs for glucocorticoid-induced osteoporosis...
Friday Sep 28, 2007
Surprise Data From ASBMR: Keep Antiresorptive Going When Adding Teriparatide
A randomized trial testing whether osteoporosis patients on long-term antiresorptive treatment benefit more from switching to teriparatide or from adding the new drug shows conclusively that it is better to add than to switch...
Tuesday Sep 25, 2007
Alendronate-Related Giant Osteoclasts Reported by Two Research Groups at ASBMR
Long-term alendronate triggers formation of a new type of giant osteoclast that might lead to mistaken diagnosis of Paget's disease that does not appear to have resorptive ability, and that can still transmit signals needed by osteoclasts for bone formation, perhaps even increasing the efficacy of teriparatide...
Thursday Aug 09, 2007
Osteoporosis Screening, Treatment Recommended for Older Men Only if History of Fracture or Over Age 80
Osteoporosis screening of all men over age 70 plus bisphosphonates for those with osteoporosis is not a cost-effective strategy for fracture prevention at current drug cost levels but might be reasonable for men 65 or older with prior fracture and for men 80 or older even without prior fracture...Schousboe JT, et al. JAMA. 2007;298:629-637.
Monday May 21, 2007
Risedronate Bests Alendronate for Fracture Reduction in REAL-World Setting
Patients receiving once-weekly risedronate have lower rates of hip and nonvertebral fractures during their first year of therapy than their counterparts who receive once-weekly alendronate...
Monday Jan 22, 2007
Merrion Reports Positive Clinical Results for Osteoporosis Drug MER 103, An Innovative Dosage Form of Alendronate (Fosamax); Absorbed More Effectively and Improved Dosing Ritual vs Fosamax
Merrion Pharmaceuticals Ltd, a privately-held international specialty pharmaceutical company engaged in the development of improved oral dosage forms of drugs that have poor bioavailability, announced the successful completion of a phase II clinical pharmacology study of MER 103.
Thursday Nov 30, 2006
Low Risk of Jaw Osteonecrosis Seen With Bisphosphonates for Osteoporosis
Osteonecrosis of the jaw has emerged as an unanticipated problem associated with bisphosphonate treatment in cancer patients, but is seldom a significant risk at the doses used for osteoporosis...
Thursday Oct 12, 2006
CardioVascular BioTherapeutics, Tufts Initiate hFGF-1 R&D for Osteoporosis
CardioVascular BioTherapeutics, Inc. announced that it has signed a sponsored research agreement with Tufts University School of Medicine to study the potential use of human acidic fibroblast growth factor-1 (hFGF-1), the active component of the Company's Cardio Vascu-Growâ„¢, to treat patients with osteoporosis...
Monday Sep 18, 2006
Novartis' Once-Yearly Reclast Investigational Infusion Osteoporosis Treatment Significantly Cuts Risk of Spine and Hip Fractures in Postmenopausal Women
Novartis Pharmaceuticals Corporation announced that phase III data presented at the 28th Annual meeting of the American Society for Bone and Mineral Research (ASBMR), September 15–19, 2006, in Philadelphia, Pa, demonstrated that its investigational, once-yearly bisphosphonate 15-minute infusion treatment, Reclast® (zoledronic acid) 5 mg, was highly effective at reducing the incidence of bone fracture in women with postmenopausal osteoporosis across the most common fracture sites—hip, spine, and nonspine (with the exception of face, fingers, and toes)—with sustained effect over 3 years.
Thursday Aug 31, 2006
Alendronate Better Than Alfacalcidol for Preventing GC-Induced Bone Loss
A randomized, double-blind clinical trial finds that alendronate is significantly better than alfacalcidol at preventing glucocorticoid-induced bone loss and reducing fracture risk...
Friday Jul 28, 2006
Strontium Ranelate Reduces Fracture Risk in Postmenopausal Women With Osteoporosis
Strontium ranelate significantly reduces the risk of veretebral fractures, increases BMD at all sites and may prevent nonspine fracture in postmenopausal women with osteoporosis, a Cochrane Review concludes. ... O'Donnell S, et al. Cochrane Database for Systematic Reviews. 2006, Issue 3.
Thursday Jun 15, 2006
Alendronate More Cost-Effective Than Teriparatide
Teriparatide could become cost-effective if its price were reduced by 60 percent, if it were given only to women with exceptionally low bone density, or if a 6-month course of teriparatide were as effective in preventing fractures at 2 years of treatment... Liu H, et al. Arch Intern Med. 2006;166:1209-1217.
Wednesday Jun 14, 2006
Alendronate More Cost-effective than Pricey Teriparati
Teriparitide could become cost-effective if it's price were reduced by 60 percent, it were given only to women with exceptionally low bone density or if a six-month course of teriparatide were proven as effective in preventing fractures as two years of treatment. ... Liu, H, et al. Arch Intern Med. 2006;166:1209-1217.
Tuesday May 30, 2006
Give Bisphosphonates and Teriparatide Sequentially, Not Together
Alendronate reduces the ability of once-daily teriparatide to stimulate new bone formation in osteoporotic men; the two drugs therefore should not be given concurrently... Finkelstein JS, et al. J Clin Endocrinol Metab. 9 May 2006; [Epub ahead of print]
Monday May 22, 2006
Second Year of FACT Trial Confirms Alendronate Advantage Over Risedronate for Preventing Bone Loss
Twenty-four-month data show that alendronate surpasses risedronate in reducing the risk of bone loss in postmenopausal women with osteoporosis... Bonnick S, et al. Clin Endocrin Metab. 24 April 2006; [Epub ahead of print]
Tuesday Mar 21, 2006
Local Bisphosphonate Administration May Improve Implant Fixation
Local treatment with the bisphosphonate alendronate combined with bone compaction may improve implant fixation... Jakobsen T, et al. Presented at: 52nd Annual Meeting of the Orthopaedic Research Society; March 18–22, 2006; Chicago, Ill. Abstract 89.
Thursday Mar 02, 2006
Denosumab Shows Promise in Phase II Study of Bone Mineral Density
Twice yearly injections of denosumab (previously known as AMG 162) significantly increased bone mineral density in the total hip, lumbar spine, distal 1/3 radius, and total body of postmenopausal women compared with placebo... McClung MR, et al. N Engl J Med. 2006;354:821-831.
Wednesday Nov 16, 2005
Amgen's Denosumab Effective in Increasing Bone Mineral Density in Postmenopausal Patients
Amgen has announced that twice-yearly subcutaneous injections of 60 mg denosumab increased bone mineral density (BMD) of the lumbar spine by 7.4% and of the total hip by 5.1% compared with 6.2% and 3.4%, respectively, for alendronate (Fosamax®) 70 mg/week over a 24-month period.
Thursday Oct 06, 2005
New Study Results Suggest That Two Courses of Parathyroid Hormone May Reduce Fracture Risk in Patients with Severe Osteoporosis
Osteoporosis patients who remain at high risk for fracture despite a course of parathyroid hormone (PTH) therapy may benefit from a second discrete course of PTH . . . Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research; September 23–27, 2005; Nashville, Tenn. Presentation 1079.
Thursday Sep 29, 2005
Long-Term Bisphosphonate Therapy Remains an Unresolved Issue
Despite concerns about long-term bisphosphonate therapy resulting in the continued suppression of bone turnover and inhibition of normal repair and replacement of damaged bone, recent clinical trials suggest that treatment for up to 10 years is not harmful ... Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research; September 23-25, 2005; Nashville, Tenn.
Wednesday Sep 28, 2005
Roche and GSK Tout Efficacy, Safety, and Convenience of Once-Monthly BonivaR Osteoporosis Therapy at ASBMR Annual Meeting
Roche Pharmaceuticals and GlaxoSmithKline presented 4 posters (2 studies) at the 27th Annual Meeting of the American Society for Bone and Mineral Research...
Tuesday Sep 27, 2005
Novel Method of Upfront Loading of Bisphosphonates Found to Improve Spinal Bone Mineral Density and Reduce Fractures
Upfront loading of oral or intravenous bisphosphonates followed by maintenance dosing may enhance the ability of these agents to reduce fracture risk compared with currently used dosing regimens... Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research; September 23-27, 2005; Nashville, Tennessee. Abstract M369.
Wednesday Aug 03, 2005
PREOSR parathyroid hormone NDA accepted for review by FDA
NPS Pharmaceuticals, Inc, of Salt Lake City, Utah, announced that the US Food and Drug Administration has accepted for review the company's new drug application (NDA) for PREOSR, a recombinant parathyroid hormone (PTH 1-84) for the treatment of osteoporosis in postmenopausal women.
Monday May 16, 2005
Higher Doses of Vitamin D May Reduce Risk of Fractures in the Elderly
In contrast to several recently published studies showing that regular supplements of calcium and vitamin D may not effectively prevent fractures, a newly published meta-analysis found that large doses of vitamin D-taken with or without calcium-reduce the risk of nonvertebral fractures in the elderly...Bischoff-Ferrari HA, et al. JAMA. 2005;293:2257-2264
Tuesday May 03, 2005
African-American Women Have Lower Risk of Fractures than Caucasians Across All Levels of Bone Mineral Density
New data suggests the need for race specific normative databases to define osteoporosis...Cauley JA, et al. JAMA 2005;293:2102-2108.
Tuesday Apr 26, 2005
Teva Challenges Merck Patent on Fosamax
The longstanding legal battle between Teva Pharmaceuticals Industries Ltd, the Israeli-based generic drug manufacturer, and Merck & Co over the validity and enforceability of Merck's patent on its once-weekly FosamaxR may now be decided by the US Supreme Court.
Monday Apr 11, 2005
FDA Approves Alendronate Sodium/Cholecalciferol (Fosamax Plus DR) for Osteoporosis; the Only Bisphosphonate With a Weekly Dose of Vitamin D
Merck & Co, Inc, received marketing approval from the US Food and Drug Administration for its once-weekly tablet containing alendronate sodium (FosamaxR) and vitamin D3 (cholecalciferol) for postmenopausal women with osteoporosis.
Wednesday Nov 24, 2004
Gender Bias May Exist in the Recognition and Treatment of Osteoporosis in Men
Although men have higher vertebral fracture rates than women, they may not get screening and treatment for osteoporosis as often or as early... Sawka AM, et al. J Rheumatol. 2004;31:1993-1995.
Monday Nov 15, 2004
EPIC Study: Alendronate's Benefits for Osteoporosis Prevention Continue Up to 6 Years
Therapy with the bisphosphonate is effective long-term in preserving bone mineral density in postmenopausal women, and should serve as a promising strategy for the prevention of osteoporosis in the post-HRT era& McClung MR, et al. J Clin Endocrinol Metab. 2004;89:4879-4885.
Wednesday Oct 13, 2004
Significant Advantages Favor Alendronate for Bone Protection
A new trial comparing 2 bisphosphonate formulations finds greater benefits with alendronate vs risedronate and no significant differences between the 2 in reported adverse events, including those associated with upper GI tolerability …Rosen C, et al. J Bone Miner Metab. 2004;19(suppl 1):S94. Abstract F412.
Tuesday Oct 05, 2004
New Focus on Osteoporosis Risk in Men
Until recently, osteoporosis, a known health risk in postmenopausal women, has attracted scant attention as a health risk for men. Although men and women alike benefit from treatment for osteoporosis, men receive treatment far less frequently, even after fractures.
|
